The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics.
In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120
The Peterson Health Technology Institute (PHTI) has added hypertension and mental health to the list of digital health technologies (DHTs) that it will review for their cl
A digital therapeutic developed by Vicore Pharma and Alex Therapeutics has been shown to reduce the psychological burden of living with pulmonary fibrosis (PF) in a pivota
Psychedelic medicines specialist MindMed has said that its LSD-based treatment MM-120 has shown efficacy in a proof-of-concept study involving patients with generalised an
NICE has followed through on plans to make a series of digital therapeutics (DTx) for adults with anxiety disorders or depression in England, although it acknowledges more
Takeda has made a strong play for a stake in the Alzheimer’s disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.